Guillain-Barré syndrome (GBS) is an autoimmune disease characterized by acute neuromuscular paralysis. Of an estimated annual number of 2628 -9575 US cases, 526 -3830 are triggered by Campylobacter infection. Research objectives were to identify the lifetime consequences of GBS and, when possible, to quantify their economic burden. The cost-of-illness method was used to calculate annual societal resources spent on medical care and lost productivity due to illness or premature death from Campylobacter-associated GBS. Estimated total costs (in US$) of Campylobacter-associated GBS ($0.2 -$1.8 billion) were added to previously estimated costs of campylobacteriosis ($1.3 -$6.2 billion) for a total annual cost from Campylobacter of $1.5 -$8.0 billion (1995 dollars). It is concluded that up to $8.0 billion in US human illness costs are spent annually because of Campylobacter infection. Economic evaluation of the other costs associated with GBS, such as physical and psychological costs, would increase these estimates.
Guillain-Barré syndrome (GBS) is the leading cause of acute these estimates to calculate improved estimates of the total societal cost of Campylobacter infections. neuromuscular paralysis in the United States now that vaccination programs have virtually eliminated polio [1, 2] . Since the first report of Campylobacter infection complicated by GBS Methods was published in 1982 [3] , evidence has accumulated that these infections are an important trigger of GBS. Campylobacter
Economic Analysis
infections are one of the most commonly recognized bacterial causes of diarrhea worldwide [4, 5] , causing an estimated 2 -
The scope of the study is the lifetime consequences of Campylobacter-associated GBS in the United States. The cost-of-illness 10 million cases of campylobacteriosis each year in the United method was used to estimate economic costs borne by society [11, States alone [6] . Campylobacteriosis is typically a self-limited 12]. Table 1 broadly outlines four cost categories for estimating gastrointestinal illness. However, serologic and cultural studies the economic costs of Campylobacter-associated GBS to patients all over the world have confirmed that §20% -40% of GBS and others in society. Most cost-of-illness studies of disease focus patients had infection with Campylobacter jejuni in the 1 -3 on costs based on market data. In particular, they estimate the weeks prior to the onset of neurologic symptoms [7 -9] . Herein, present value of lifetime medical costs and lost productivity (i.e., the term Campylobacter shall be used to include both C. jejuni lost income and household production caused by the illness) to and Campylobacter coli because infections caused by these 2 obtain partial estimates of annual costs [15] [16] [17] [18] bacter-associated GBS include a broad spectrum of services and Although GBS is a complication in only a small percentage treatments, such as the costs of hospitalization, mechanical ventilation, plasma exchange, physician visits, intravenous immunoglobuof Campylobacter infections, the severity of GBS and its correlin, and medication. Costs for vocational or physical rehabilitation, sponding potential for high costs indicate the need for estimatresidential care, home modifications, and travel to medical care ing the costs of Campylobacter-associated GBS to improve may also be estimated.
estimates of the total societal cost from Campylobacter infecProductivity losses occur when there is a reduction or cessation tions. The objectives of this study were to estimate the annual of work due to premature mortality and morbidity [19] . Losses for cost of Campylobacter-associated GBS illnesses and to use those who die and for those who miss work are typically represented by the present value of future earnings (i.e., the earnings the persons would have accumulated in the absence of the illness). Productivity losses include deaths due to GBS and situations in The views expressed in this paper are not official policy of the US Departmethod to estimate the value of a statistical life [20] . [13, 14] . * Costs to industry linked with foodborne disease -associated GBS may include costs of product liability, insurance administration, and reduced product demand; product liability costs may include cost of pain and suffering.
dollars [22] . The Landefeld and Seskin formula was used in this ones, changes in residence, and job loss. There is no widely accepted method for quantifying psychological costs. analysis.
Physical costs. Physical costs of GBS include pain, suffering, Other social costs. Other social costs of GBS are psychological costs that impact society (beyond the emotional well-being of and disfigurement (table 1) . There is no accepted procedure for quantifying these costs. The inability to quantify pain and suffering patients with GBS and their family and friends). These costs include segregation, isolation, discrimination, and economic depenis particularly troublesome for GBS because up to 65% of patients with GBS report neurologic pain [23] .
dence. Social costs of GBS to society may include the loss of productive workers to society (temporary or permanent) and inPsychological costs. Indicators of psychological costs are low self-esteem, grief, worry, depression, emotional problems, and creased economic dependence on society (e.g., social assistance). Again, these costs were not quantified in this analysis. other reductions in the quality of life caused by the disability, deficits, economic dependence, and social isolation that typically accompany the disease [19] . Patients with GBS may be depressed and anxious about when the pain will cease, the extent that they Assumptions may have a permanent disability or lingering minor deficits, and whether they face a premature and impending death. Also, given
Incidence of GBS. The annual incidence of GBS in the United States is Ç1-2 persons/100,000 population [7, [23] [24] [25] , which the widespread occurrence of underinsured people and the high cost of hospitalization, financial concerns may add to the mental translates into 2628-5256 new GBS patients each year. However, the National Center for Health Statistics' National Hospital Disburden. Psychological costs may also include emotional consequences resulting from GBS-associated divorce, death of loved charge Survey data showed an annual average of 9575 patients / 9d36$$de11 10-24-97 14:28:50 jinfa UC: J Infect given our desire to be conservative in estimating costs, we adjusted ‡ [7, 24] .
outcome probabilities for ventilated patients [30] to reflect this § [26] .
lower overall lethality while maintaining the outcome probabilities x Estimated at 20% -40% of all GBS patients [7, 9] ; 526 patients Å 20%
for patients not requiring ventilation [30] . Among ventilated paof 2628 patients with GBS and 3830 patients Å 40% of 9575 patients with GBS.
tients, 63% resumed work, 27% did not return to work, and 10% died. Those who returned to work included those who found less demanding jobs. with GBS (3.64/100,000 population) for 1979-1993 [26] . ThereFor those patients who returned to work, annual productivity fore, the range used in this study was 2628-9575 GBS patients losses per patient were estimated by multiplying the baseline daily in the United States annually (table 2) .
income by the average number of days of work missed. The basePercentage of patients with GBS who had antecedent Campyloline daily income by age group was derived from the usual weekly bacter infections. It was estimated on the basis of cultural and earnings of employed part-time and full-time wage and salary serologic studies [7] [8] [9] , that 20%-40% of patients with GBS have workers reported by the Bureau of Labor Statistics, adjusted for antecedent Campylobacter infections.
the labor force participation rate, weekend earnings, and fringe Medical costs. Two age and medical treatment categories were benefits (a 40% increase in wages to account for benefits such as used to estimate costs. As supported by recent studies [27] [28] [29] , it health, vacation, and retirement). It was also assumed that the was assumed that 20% of patients with GBS were mechanically value of an hour of time is the same for patients of any race, ventilated. Separate cost analyses were done for these patients. On gender, or geographic location in the United States. For patients the basis of a detailed study of mechanically ventilated GBS pareturning to work, it was assumed that 2 days are spent at home tients, a mean age of 30 years was assumed for patients not requirrecuperating for each day hospitalized. ing mechanical ventilation; mechanically ventilated patients were assumed to have a mean age of 47 years [30] . On the basis of an informal survey of neurologists on the Medical Advisory Board NOTE. Amounts may not total due to rounding. Total fees for physician care, laboratory tests, and other medical items are assumed to be equal to hospital room costs but are updated with physicians' consumer price index (CPI) instead of hospital CPI. It is assumed that cost of intensive care unit (ICU) hospital room is double cost of regular room per day. Item Å days or treatments, as appropriate; NA Å not applicable. medical care for a mechanically ventilated patient was tion, the average number of days of work missed was 41; mechanically ventilated patients missed an average of 211 days Ç$329,900 (includes 68.4 ICU days and 30.1 days in a regular hospital room). The total annual medical cost for all patients of work. The average daily productivity loss per person was estimated at $115 for persons 30 years of age and $148 for with Campylobacter-associated GBS is estimated to be $57.7 -$420.5 million.
persons 47 years old. The total loss due to days of work missed was $1.6 -$11.7 million for patients not requiring mechanical Productivity costs. Between 407 and 2965 GBS patients with antecedent Campylobacter infections were able to return ventilation (assumed mean age, 30 years), and it was $2.1 -$15.1 million for patients who were mechanically ventilated to work (table 4). For patients not requiring mechanical ventila- 
